Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

By afschroeder • February 6, 2026

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns W, Narang A, Qadan M, Castillo CF, Lillemoe KD, Wo J, Hong T, Donahue TR. Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. J Gastrointest Surg. 2026 Feb 3:102358. doi: 10.1016/j.gassur.2026.102358. Epub ahead of print. PMID: 41644009.

Tags: Hematology/Oncology, neoadjuvant therapy, pancreatic cancer, Publications, Sterotactic Body Radiation Therapy

Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study

LeVee A, Jacob S, Fisch S, Face C, Chengappa M, Chaudhry S, Baclig N, Soliman A, Ruel N, Wong M, Tsai K, Kang I, Kordic[...]

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig[...]

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]